BIORA THERAPEUTICS INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch BIORQ and buy or sell other stocks, ETFs, and their options commission-free!

About BIORQ

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. 

CEO
Aditya P. Mohanty
CEOAditya P. Mohanty
Employees
58
Employees58
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2010
Founded2010
Employees
58
Employees58

BIORQ Key Statistics

Market cap
452.27
Market cap452.27
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
28.70
Average volume28.70
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.34
52 Week high$0.34
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

BIORA THERAPEUTICS INC(BIORQ) stock is priced at $0.00, giving the company a market capitalization of 452.27.

BIORA THERAPEUTICS INC(BIORQ) stock opened on 2026-03-02 at —. The price climbed to — and dipped to —.

BIORA THERAPEUTICS INC(BIORQ) shares are trading with a volume of 0, against a daily average of 28.7.

In the last year, BIORA THERAPEUTICS INC(BIORQ) shares hit a 52-week high of $0.34 and a 52-week low of $0.00.

In the last year, BIORA THERAPEUTICS INC(BIORQ) shares hit a 52-week high of $0.34 and a 52-week low of $0.00.

People also own

Based on the portfolios of people who own BIORQ. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.